Business Context and Reporting Period
Company: AN2 Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2026
Event: Approval of a stock option repricing for all outstanding options granted under the 2017 and 2022 Equity Incentive Plans.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on equity compensation adjustments.
Material Changes
- Option Repricing: The Board reduced the exercise price of all eligible outstanding stock options to $3.91 per share, reflecting the closing stock price on March 19, 2026.
- Original Prices: Prior to this action, exercise prices for named executive officers ranged from $6.60 to $17.88 per share.
- Repricing Conditions: A "Premium End Date" mechanism was established. If options are exercised or employment terminates before the earliest of September 19, 2027, a change in control, or death/disability, the holder must pay the original, higher exercise price.
Management Commentary and Risks
Management Rationale: The Board determined the repricing is in the Company's best interest to retain and motivate participants without incurring the stock dilution associated with new equity grants or the cash expenditures of additional salary.
Executive Impact:
- Eric Easom (CEO): 742,649 Eligible Options.
- Lucy Day (CFO): 221,965 Eligible Options.
- Joshua Eizen (CLO/COO): 142,150 Eligible Options.
Risks/Contingencies: The filing does not disclose specific financial risks or contingencies beyond the conditional nature of the option repricing (the Premium End Date requirement).
Investor Verification Checklist
- Verify the current trading price of AN2 Therapeutics common stock (ANTX) relative to the new $3.91 exercise price.
- Review the full text of the 2017 and 2022 Equity Incentive Plans to understand the specific terms of the "Premium End Date" clause.
- Assess the potential dilution impact of the repriced options if the Premium End Date conditions are met.
- Confirm the total number of outstanding options and the aggregate number of shares reserved for issuance under the Plans.